Overcoming Limitations in the Availability of Swabs Systems Used for SARS-CoV-2 Laboratory Diagnostics

Manfred Nairz (✉ manfred.nairz@i-med.ac.at)

Department of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology, Pneumology,
Medical University of Innsbruck, Innsbruck, Austria

Rosa Bellmann-Weiler

Medical University of Innsbruck

Miriam Ladstätter

University Hospital of Innsbruck

Falko Schüllner

University Hospital of Innsbruck

Martina Zimmermann

Medical University of Innsbruck

Anna-Maria Koller

Medical University of Innsbruck

Silvia Blunder

Medical University of Innsbruck

Helene Naschberger

Medical University of Innsbruck

Werner Klotz

Medical University of Innsbruck

Manfred Herold

Medical University of Innsbruck

Sylvia Kerndler

University Hospital of Innsbruck

Martina Jeske

University Hospital of Innsbruck

David Haschka

Medical University of Innsbruck

Verena Petzer

Medical University of Innsbruck

Andrea Schroll

Medical University of Innsbruck

Thomas Sonnweber

Medical University of Innsbruck

Ivan Tancevski

Medical University of Innsbruck

Gernot Fritsche

Medical University of Innsbruck

Mariana E. G. de Araujo

Medical University of Innsbruck

Taras Stasyk

Medical University of Innsbruck

Lukas A. Huber

Medical University of Innsbruck

Andrea Griesmacher

University Hospital of Innsbruck

Igor Theurl

Medical University of Innsbruck

Günter Weiss

Medical University of Innsbruck

Research Article

Keywords: COVID-19, SARS-CoV-2, Sensitivity, Pharyngeal Swab, Specimen Collection Set, Diagnostic Screening Program.

Posted Date: June 23rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-37549/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

The diagnosis of COVID-19 relies on the direct detection of SARS-CoV-2 RNA in respiratory specimens by RT-PCR. The pandemic spread of the disease caused an imbalance between demand and supply of materials and reagents needed for diagnostic purposes including swab sets. In a comparative effectiveness study, we conducted serial follow-up swabs in hospitalized laboratory-confirmed COVID-19 patients. We assessed the diagnostic performance of an *in-house* system developed according to recommendations by the US CDC. In a total of 96 swabs, we found significant differences in the accuracy of the different swab systems to generate a positive result in SARS-CoV-2 RT-PCR, ranging from around 50 to 80%. Of note, an *in-house* swab system was superior to most commercially available sets as reflected by significantly lower Ct values of viral genes. Thus, a simple combination of broadly available materials may enable diagnostic laboratories to bypass global limitations in the supply of swab sets.

Introduction

Coronavirus disease 2019 (COVID-19) is the respiratory tract infection caused by severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2) ¹⁻³. The diagnosis of COVID-19 largely relies on the direct detection of viral ribonucleic acid (RNA) in respiratory specimens ^{4,5}. In most cases, specimens are obtained from the upper respiratory tract by swabbing the posterior nasopharyngeal or oropharyngeal wall using commercially available sets ^{6,7}. These sets typically consist of a plastic swab and a tube containing universal or virus transport medium (UTM or VTM, respectively) in compositions and quantities that differ between the manufacturers.

Once collected, respiratory specimens are most commonly analyzed in diagnostic laboratories by reverse transcription polymerase chain reaction (RT-PCR) to detect viral RNA ^{8,9}. Some RT-PCR tests are developed *in-house*, often following recommendations of reference laboratories and official institutions ¹⁰⁻¹². Other tests are commercially available and are in research use only (RUO) status or certified as *in-vitro* diagnostics (IVD) ¹³⁻¹⁶. Typically, RTPCR tests are run in multiplex to detect two viral genes and one internal control in the same reaction well, tube or cartridge.

In many regions hit by the COVID-19 pandemic, health authorities have put containment strategies in place ¹⁷. Among these, broad RT-PCR testing of asymptomatic or symptomatic individuals, restrictions in transportation, tracing of social contacts, barrier precautions, isolation and quarantine measures are the most common ones ¹⁸⁻²¹. While the detection of SARS-CoV-2 by RT-PCR is highly specific for COVID-19, the sensitivity of the method is limited by several factors, including the employed swab sets ²²⁻²⁴. Therefore, in suspected cases, clinical, biochemical and radiological findings are important in confirming the diagnosis of COVID-19 ²⁵⁻²⁷.

Broad screening by RT-PCR requires accurate planning and concerted use of the material and personnel resources for the proper collection, administration and actual molecular analytics of specimens ^{5,28-30}. On a large scale, these steps and the subsequent interpretation and submission of results challenge the

ordering, warehousing and other infrastructural aspects of diagnostic laboratories ³¹. Therefore, large regional and national screening programs require enormous effort in preanalytical, analytical and postanalytical phases of laboratory diagnostics.

Because of the unprecedentedly high number and urgency of tests requested, diagnostic laboratories in endemic regions including ours faced the challenge to acquire sufficient amounts of materials and reagents. Despite established supply chains, the most striking shortages occurred in specimen collection sets and RT-PCR reagents ³².

As for RT-PCR, several national reference laboratories developed and published primers, probes and test conditions ^{10,15}. With a little delay, many manufacturers entered the growing market with commercially available kits whose status ranged from RUO products to *in-vitro* diagnostics with European CE marking (CE-IVD). Due to the prompt response of the biomedical industry and the growing availability of test kits for RT-PCR, limitations moved towards more general materials and reagents such as swabs and chemicals for RNA extraction. In our study, we systematically validated commercially available swab sets as well as a system produced *in-house* for their practical utility in collecting oropharyngeal swabs and their biochemical compatibility with the subsequent diagnostic RT-PCR for SARS-CoV-2.

Results

The positivity rate of follow-up SARS-CoV-2 RT-PCR results from confirmed cases varies between swabs systems

We enrolled symptomatic patients hospitalized for acute laboratory-confirmed COVID-19 at the Department of Internal Medicine at the University Hospital of Innsbruck, Austria. Oropharyngeal swabs were taken for follow-up within the first five days after admission to the hospital. The diagnostic effectiveness of different systems used for follow-up swabs that were serially taken on one occasion was retrospectively analyzed.

We compared the utility of different swab systems in confirming the initial positive RT-PCR result that led to the classification of the case as laboratory-confirmed COVID-19. We saw a wide range in the percentage of results that were repetitively positive using the same RT-PCR method within five days of the initial test. Specifically, the percentages ranged between 50.0% and 81.3%. Interestingly, none of the collection systems could confirm the initially positive RT-PCR result to 100% and only three swabs sets reached an accuracy in confirming the initial results with 70% or more.

Initially, we had two swab sets available because they were already validated for use in the laboratory diagnosis of influenza by RT-PCR: The swab set with UTM obtained from Copan® reached a mean sensitivity of 70.0% (95% CI of mean 48.0% – 92.0%) in the SARSCoV-2 RT-PCR. The swab set with VTM from Cepheid® reached 71.4% (95% CI of mean 44.4% – 98.5%). For comparison, the *in-house* system containing VTM mixed according to a CDC recipe reached 81.3% sensitivity (95% CI of mean 67.0% –

95.6%) (Figure 1). The reconfirmation of the initial positive PCR result was much lower when using Sarstedt® dry swabs followed by elution with an isotonic saline solution or the BD SurePath® system, intended for cervical swabs in liquid-based gynecologic cytopathology and widely used for Human Papilloma Virus (HPV) diagnostics³³. The latter two systems produced only 50.0% positive results (95% CI of mean 22.5% – 77.5% for the SurePath® system and 26.0% – 74.0% for the dry swab method, respectively).

The analytical sensitivity of SARS-CoV-2 RT-PCR is dependent on the swab system used for specimen collection

To further substantiate these findings, we looked into Ct threshold cycle (Ct) values of our RT-PCR results. Although the Altona® RealStar® SARS-CoV-2 RT-PCR is a qualitative RTPCR by design, the Ct values are proportional to the amount of RNA present in the sample.

We thus analyzed the Ct values for the SARS-CoV-2 envelope (SARS-CoV-2 E) gene, for the SARS-CoV-2 spike (SARS-CoV-2 S) gene and for the internal control (IC) of all positive follow-up samples. When we compared the SARS-CoV-2 positive samples collected with the *in-house* system to all other systems combined, we found that the Ct values of the viral E gene and viral S gene were significantly lower for the *in-house* system. This was again indicative of high analytical sensitivity of the *in-house* system as compared to commercially available swab sets (Figure 2; inverse y-axis).

In detail, we found that the Ct values for the E gene obtained with the *in-house* swab set were the lowest, amounting to 28.65 (95% CI of mean 26.92 – 30.38), which indicated the highest analytical sensitivity (Supplemental Figure 1A; inverse y-axis). The Ct values for the E gene obtained with the mentioned Cepheid® swab system were the second-lowest, amounting to 29.45 (95% CI of mean 24.04 – 34.86). When assessing the S gene, we saw that the Ct values with the *in-house* system were the second-lowest, amounting to 31.80 (95% CI of mean 29.55 – 34.06) (Supplemental Figure 1B; inverse y-axis). Notably, the Ct values for the IC were very similar across all swab sets tested (Supplemental Figure 1C; inverse y-axis).

In 19 out of 34 serial swabs, we had Ct values of direct comparisons between the *in-house* system and either of our two sets originally validated for pharyngeal swabs, from Copan® or Cepheid®, available. Strikingly, we observed significantly lower Ct values for the E gene and S gene but not for the IC using the *in-house* system (Figure 3; inverse y-axis). This indicated that the *in-house* swab system indeed formed a suitable basis for highly sensitive detection of SARS-CoV-2 RNA by RT-PCR.

The volume of virus transport medium used for specimen collection has a minor effect on the diagnostic

performance of SARS-CoV-2 RT-PCR

Next, we asked whether the volumes of the liquid media provided may affect the sensitivity of the swab system for subsequent SARS-CoV-2 RT-PCR. We found that the volume of the VTM present in the *in-house* system had a minor effect on the Ct values for the viral E gene which were very similar for sets with 1.2ml, 2ml, 3ml and 4.3ml of VTM (Supplemental figure 2A; inverse y-axis). The same was true for commercially available swab systems which use different volumes of liquid media according to the manufacturers' specifications. A very similar pattern of Ct values was observed for the viral S gene (Supplemental figure 2B; inverse y-axis), while for the IC, Ct values were essentially the same across the swabs systems compared (Supplemental figure 2C; inverse y-axis).

Organic compounds in swabs may inhibit SARS-CoV-2 RT-PCR

Since back orders not only affected tubes with VTM but also plastic swabs, we combined the *in-house* tube containing 1.2ml of VTM with either of six different swabs. We used the Puritan® PurFlock Ultra Flocked Swab (Pure), the Copan® FLOQSwabs Copan Flocked Swabs (Flocked), the Copan® CLASSIQSwabs (Classic), the mwe medical wire DRYSWAB (Dry), a clean room product intended for the cleaning of technical devices termed IAB® Reinraumprodukte GmbH Polyester Swab PS3605 (Technical) and the wooden Raucotupf® Cotton tipped Applicator (Wooden). In serial swabs from four individual patients, we found that the viral E gene was detectable with comparable Ct values in all samples but not in that one taken with the wooden cotton-tipped swab (Supplemental figure 3A; inverse y-axis). The viral S gene was detectable in three out of four samples taken with most swabs. However, the viral S gene was undetectable in two out of four samples taken with the technical swab and was undetectable in all samples taken with the wooden cotton-tipped swab (Supplemental figure 3B; inverse y-axis).

The IC was similar across all swab systems but lower, albeit not significantly, in the group taken with the wooden cotton-tipped swab in which one IC remained undetectable, resulting in a single invalid test result (Supplemental figure 3C; inverse y-axis). Therefore, we next compared the wooden cotton-tipped swab with all other variants of swabs and saw that its sensitivity as deduced from the higher Ct values of RT-PCR results was significantly lower (Figure 4; inverse y-axis).

The virus transport medium stabilizes SARS-CoV-2 RNA during storage in the refrigerator

Next, we tested the ability of the *in-house* swabs system to preserve viral RNA for detection by RT-PCR. To this end, we measured aliquots of samples after storage at 4°C overnight (O/N), for 24 hours (1d), 72 hours (3d) or 168 hours (7d) by RT-PCR. We saw that the Ct values of the viral E gene, viral S gene and the IC remained fairly stable during the observation period (Figure 5A, B, C; inverse y-axis). The addition of

4,000U/ml of an RNase inhibitor for 72 hours had no substantial effect on Ct values of the E gene in specimens collected with the *in-house* (white bars) or Copan® system (grey bars) used as original reference (Supplemental figure 4; inverse y-axis). These results also indicate that the sterile Sarstedt® tubes, used for the *in-house* system that have up to now not reported to be free of RNases, could be used without the addition of an RNase inhibitor.

Discussion

RT-PCRs for SARS-CoV-2 are performed for various indications. First, asymptomatic individuals may be screened because they had previously been in close contact with somebody diagnosed with COVID-19. In this setting, it may be required to test several times to confirm or rule out an infection of the test subject. This approach is considered a public health measure, because it detects SARS-CoV-2 infection early in pre-symptomatic subjects and enables the breach of infection chains^{13,34,35}. Second, asymptomatic health-care workers and other staff working in hospitals or nursing homes, who are in contact with vulnerable groups of patients, can be screened for the safety of both co-workers and patients^{36,37}. Third, individuals with symptoms suggestive of COVID-19 such as fever, malaise, dry cough or loss of taste or smell ought to be tested for diagnostic purposes and initiation of subsequent specific health care measures.

The majority of diagnostic PCRs for SARS-CoV-2 are performed for screening of asymptomatic persons or in a diagnostic approach of patients with mild and unspecific symptoms and low to medium pre-test probability of actually carrying the disease. Therefore, PCR testing needs to be conducted on a large scale and with high sensitivity not only in a given country but worldwide. As a consequence, millions of swabs and PCR kits are needed globally during the ongoing pandemic, challenging resources and supply chains.

Confronted with limitations in resources and logistics, we investigated the utility of several kinds of swab sets in a well-defined cohort of subjects. We recruited symptomatic patients who were confirmed to have COVID-19 by RT-PCR and who were hospitalized for supportive care such as conventional oxygen therapy. These patients were re-swabbed for follow-up within five days after the initial positive RT-PCR. The focus of our study was the technical validation of alternative swabs systems used to collect oropharyngeal specimens and their sensitivity in identifying PCR-confirmed cases. However, one has to admit that PCR results may turn negative after a short period of time, at least in not severely affected subjects³⁸.

As applies for most other sections of industry, biomedical companies which are involved in molecular diagnostics of COVID-19 and other diseases rely on central manufacturing and cross-border delivery to serve a global market. Their repertoire may extent from simple materials such as plastic swabs and tubes to highly sophisticated reagent kits and diagnostic platforms. In late March 2020, less than four weeks after the COVID-19 pandemic reached Austria, we started to experience severe shortages in materials and reagents in the diagnostic laboratories at the University Hospital of Innsbruck. The earliest and largest limitations affected pharyngeal swab sets because factories producing them for the global market are located in regions most heavily affected by COVID-19 such as Lombardy in Northern Italy. Therefore, we

placed utmost priority on the active search for alternative swab sets. By April, the number of SARS-CoV-2 PCR tests requested rose to more than 400 per day at the University Hospital of Innsbruck. This meant a massive challenge for the local resources of a tertiary centre.

The earliest and simplest way to approach these limitations was to use dry plastic swabs which are compatible with PCR as recommended by some authorities. However, collecting an upper respiratory sample with a dry swab and eluting the viral RNA contained in the specimen with normal saline may reduce the diagnostic sensitivity of the subsequent RNA extraction and RT-PCR, consequently ^{39,40}. This limitation has been known for other pathogenic viruses and was confirmed for SARS-CoV-2 in our study (Figure 1). Therefore, we aimed to improve the yield of viral RNA by mixing a VTM *in-house* from a small number of components that are more broadly available because many vendors deal with those reagents. However, we also purchased other specimen collection sets and included them in our comparative analysis. For instance, sets used in gynecology or urology which are suitable for the detection of *Chlamydia*, *Mycoplasma* and *Ureaplasma* spp. but also HPV, were evaluated to collect specimen from the posterior oropharyngeal wall. Furthermore, the *inhouse* VTM was used in combination with several swabs. However, when using one with a wooden stalk and a cotton tip, we failed to detect SARS-CoV-2 by RT-PCR. Concretely, we saw that the Raucotupf® swab resulted in high Ct values for the viral E gene and undetectable levels of the viral S gene as surrogates of poor sensitivity. Organic compounds present in wood and cotton could have inhibited PCR reactions. Specifically, tannic acid present in wood has been demonstrated to inhibit Taq polymerase ⁴¹.

Another option to circumvent backorders in plastic swabs is to produce them in a 3D printer as recently validated in other laboratories ^{42,43}. Besides, manufacturers from other branches of industry, which are familiar with the production of plastic ware, may start to produce customized tubes. On the one hand, these ideas do not resolve the limitation of sensitivities of dry swabs. On the other hand, tubes for molecular biology applications may require specifications and purities not all companies can provide. This may be especially relevant for RNases that can contaminate surfaces including the outside of swabs or the inside of tubes or being present in biological samples ⁴⁴. However, in our validation, we did not see any effect of the addition of an RNase inhibitor that would prevent the negative effects of possible contamination of collection tubes. Thus, when tubes are produced under clean room conditions and handled with gloves during sampling and laboratory work-up, RNases may not be of concern for detecting SARS-CoV-2 by RT-PCR.

Companies that produce complete swab sets with VTM typically do not report their detailed composition. While the components used are often disclosed upon request, the exact quantities present in the mixture are usually not provided. Therefore, users have to rely on recommendations and recipes published by health authorities and institutions such as the CDC. Importantly, the *in-house* system produced according to CDC recommendations by the Innsbruck Hospital Pharmacy was also low-priced. Concretely, the costs for its constituents were approximately €0.45 per unit, not including the plastic swab. Therefore, the *in-house* system was highly efficient not only from a diagnostic but also from an economic point of view.

Our study has several limitations. First, the study was monocentric by design, precluding general recommendations. Second, we relied on the Realstar® RT-PCR system provided by Altona® which is in RUO status and detects the E gene and the S gene along with an internal extraction and amplification control. However, when we validated its diagnostic performance in comparison with the Roche® Cobas SARS-CoV-2 test or an *in-house* RT-PCR for SARSCoV-2 using the primers and probes published by the CDC, we found no significant differences between these methods, suggesting that our results may not depend on a specific target sequence or type of polymerase. Third, we only enrolled hospitalized patients with moderate symptoms. Fourth, our study exclusively deals with oropharyngeal swabs, a common specimen taken for SARS-CoV-2 PCR ⁴⁵ because we had observed in that advance serial sampling at the posterior oropharyngeal wall is technically less challenging for healthcare professionals, physically less demanding for test subjects and thus more reproducible than in the nasopharyngeal cavity. Fifth, due to a limited number of eligible patients, the sample size of our study is rather small and further studies which have a prospective and multicentric design or recruit out-patients as well may be required for more general conclusions.

One of the most striking findings of our study is that none of the swabs systems used could confirm the previous RT-PCR diagnosis of COVID-19 with 100% accuracy. In fact, the *inhouse* system reached the highest percentage of *bona fide* true positive results, concretely, 81.3%. While these numbers may first appear counterintuitively low, they support the idea that the timing and mode of specimen collection, transport and storage conditions as well as the sensitivity of the subsequent RT-PCR are critical for an accurate diagnosis. Therefore, when the clinical suspicion for infection is high, repeated testing may be required which will consume additional resources, though ^{46,47}. Furthermore, many reports suggest that some patients with COVID-19 can display intermittently or continuously negative RT-PCR results in upper respiratory specimens ^{48,49}. Unfortunately, the type of swab sets used is not reported in many studies rendering comparisons and general conclusions unnecessarily difficult.

In summary, our study emphasizes that materials and methods have to be thoroughly validated in diagnostic laboratories. This is especially relevant when alternative systems are adapted ⁵⁰. We could also demonstrate that, by employing published protocols, the cooperation of the diagnostic laboratories and the Hospital Pharmacy at a tertiary center was able to circumvent limitations in the regional supply of swab sets from the global market. Our results argue for stringent standardization of specimen collection not only for diagnostic SARS-CoV-2 PCR but also for intervention studies on COVID-19 many of which include RT-PCR results as secondary end points.

Materials And Methods

The swab/media sets tested were as follows (1) the *in-house* system, consisting of 1.2ml of VTM (for virus transport medium), prepared according to CDC recommendations and filled into a 4.5ml Sarstedt polypropylene tube, (2) the Copan UTM® (order number 305C), containing 3ml of UTM® (for universal transport medium), (3) the Cepheid GeneXpert Xpert® Nasopharyngeal Sample Collection Kit for Viruses, containing 3ml of VTM, (4) the Abott multi-Collect Specimen Collection Kit, containing 1.2ml media, (5)

the Roche cobas® Dual Swab Sample Kit, containing 4.3ml PCR Media (6) the Bioer Nasopharyngeal Swab, containing 2ml of Sample Preservation Fluid, (7) a neutral Sarstedt Rayon viscose swab (order number 80.1301), used in combination with a 4.5ml Sarstedt polypropylene tube and 1ml of normal saline and (8) the BD SurePath® containing 10ml Preservative Fluid.

The *in-house* system was prepared in the Innsbruck Hospital Pharmacy and validated in the Infectious Diseases (ID) laboratory according to the Austrian Medical Devices Act. To this end, 1.2ml of VTM were filled into a 4.5ml Sarstedt polypropylene tube (order number 60.557.001). The mixture of the VTM was published by the CDC. It was based on Hanks Balanced Salt Solution (1xHBSS) with calcium and magnesium ions, without phenol red, and contained 2% of heat-inactivated fetal bovine serum (FBS), 100µg/ml gentamicin and 0.5µg/ml amphotericin B. The components were mixed under aseptic conditions in a laminar air flow unit and remained sterile as confirmed by microbiologic testing. Moreover, the *inhouse* system could be stored at 2-8°C prior to use for at least 8 weeks without loss of sensitivity in the RT-PCR for SARS-CoV-2 (details not shown).

The swabs used in combination with the *in-house* system were as follows (1) the Puritan PurFlock Ultra Flocked Swab, (2) the Copan FLOQSwabs Copan Flocked Swab, (3) the Copan CLASSIQSwab, (4) the MWE medical wire DRYSWAB, (5) the clean room product IAB Reinraumprodukte GmbH Polyester Swab (order number PS3605) and (6) the Lohmann&Rauscher Raucotupf® Cotton tipped Applicators (order number DE-01369204).

For RT-PCR, we used the AltoStar® Automation System AM16 in combination with the AltoStar® Purification Kit 1.5 and the RealStar® SARS-CoV-2 RT-PCR Kit 1.0 RUO (order number 821005). RT-PCR was run for 45 cycles on a C1000 Touch Thermal Cycler manufactured by Bio-Rad® Laboratories and provided by Altona®. The RT-PCR result of a given sample was considered positive for SARS-CoV-2 when either the E gene or the S gene or both viral genes were detectable. When neither one of the viral genes nor the internal control (IC) were detectable, the RT-PCR was considered invalid. Oropharyngeal samples were kept on room temperature from specimen collection to acceptance in the ID laboratory. Unless otherwise specified, samples were then stored overnight in the refrigerator at 2-8°C. Thereafter, the plastic swab was removed and the collection tube containing transport medium or preservation fluid was kept on room temperature until nucleic acid extraction. Nucleic acid extraction and RT-PCR were performed in a closed, CE-IVD approved system.

Ethics

Oropharyngeal swabs were collected for follow up of COVID-19 patients who were treated on wards dedicated to normal care in ID at the Department of Internal Medicine, University Hospital of Innsbruck, and for technical validation of the systems in the ID laboratory. Written informed consent was obtained for the collection, processing and retrospective comparative analysis of the swab systems. The study was approved by the local ethics committee of the Medical University of Innsbruck (approval numbers 1091/2020, 1103/2020 and 1167/2020).

Statistics

Statistical analysis was performed with the GraphPad Prism 5 software package. Data distribution and homoscedasticity were analyzed. Accordingly, we used Fisher's exact test to analyze categorical variables and Mann-Whitney U test, Kruskal-Wallis or Wilcoxon test to analyze continuous data. Dunn correction was applied to adjust alpha error for multiple testing.

Declarations

Acknowledgements

We thank Kaoru Schnaiter, Cornelia Winkler, Thomas Steirer and Peter Obrist, MD for providing materials.

Research in our laboratory is supported by grants from the Austrian Research Fund (FWF, P 33062, to MN), the Christian Doppler Society (to GW), the Tyrolean Research Fund (TWF, to MN) and by the 'Verein zur Förderung von Forschung und Weiterbildung in Infektiologie und Immunologie an der Medizinischen Universität Innsbruck'. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

MN, RBW, ITheurl and GW designed the study. ML, FS, SK, MJ, MEGA, TStasyk and LAH prepared essential reagents. MZ, AMK, SB and HN performed RT-PCR. DH, VP, AS and GF recruited patients. MH, AG and ITheurl interpreted results. TSonnweber and MN performed statistical analysis. RBW, DH, VP, TSonnweber, ITancevski and MN obtained ethical approval. MN and GW wrote the main manuscript text and MN prepared the figures. All authors reviewed the manuscript.

Competing interests statement

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

1. Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 382, 727-733 (2020), doi:10.1056/NEJMoa2001017.
2. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 579, 270-273 (2020), doi:10.1038/s41586-020-2012-7.
3. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265-269 (2020), doi:10.1038/s41586-020-2008-3.

4. Tang, Y. W., Schmitz, J. E., Persing, D. H. & Stratton, C. W. The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges. *J Clin Microbiol* (2020), doi:10.1128/JCM.00512-20.
5. Cheng, M. P. et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review. *Ann Intern Med* (2020), doi:10.7326/M20-1301.
6. Wang, X. et al. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. *Int Infect Dis* 94, 107-109 (2020), doi:10.1016/j.ijid.2020.04.023.
7. Fang, F. C., Naccache, S. N. & Greninger, A. L. The Laboratory Diagnosis of COVID-19– Frequently-Asked Questions. *Clin Infect Dis* (2020), doi:10.1093/cid/ciaa742.
8. Loeffelholz, M. J. & Tang, Y. W. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. *Emerg Microbes Infect* 9, 747-756 (2020), doi:10.1080/22221751.2020.1745095.
9. Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. *Sci Transl Med* 12 (2020), doi:10.1126/scitranslmed.abc1931.
10. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25 (2020), doi:10.2807/1560-7917.ES.2020.25.3.2000045.
11. Buckner, F. S. et al. Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. *Clin Infect Dis* (2020), doi:10.1093/cid/ciaa632.
12. Lu, X. et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis* 26 (2020), doi:10.3201/eid2608.201246.
13. Bohmer, M. M. et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis* (2020), doi:10.1016/S1473-3099(20)30314-5.
14. Sirunyan, A. M. et al. Extraction and validation of a new set of CMS pythia8 tunes from underlying-event measurements. *Eur Phys J C Part Fields* 80, 4, doi:10.1140/epjc/s10052-019-7499-4.
15. Uhteg, K. et al. Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays. *J Clin Virol* 127, 104384 (2020), doi:10.1016/j.jcv.2020.104384.
16. Pfefferle, S., Reucher, S., Norz, D. & Lutgehetmann, M. Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system. *Euro Surveill* 25, doi:10.2807/1560-7917 (2020).ES.2020.25.9.2000152.
17. Maier, B. F. & Brockmann, D. Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. *Science* 368, 742-746 (2020), doi:10.1126/science.abb4557.
18. Zitek, T. The Appropriate Use of Testing for COVID-19. *West J Emerg Med* 21, 470-472 (2020), doi:10.5811/westjem.2020.4.47370.
19. Rivett, L. et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife* 9 (2020), doi:10.7554/eLife.58728.
20. Prather, K. A., Wang, C. C. & Schooley, R. T. Reducing transmission of SARS-CoV-2. *Science* (2020), doi:10.1126/science.abc6197.

21. Chu, D. K. et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* (2020), doi:10.1016/S0140-6736(20)31142-9.
22. Li, Y. et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* (2020), doi:10.1002/jmv.25786.
23. Liu, R. et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. *Clin Chim Acta* 505, 172-175 (2020), doi:10.1016/j.cca.2020.03.009.
24. Green, D. A. et al. Clinical Performance of SARS-CoV-2 Molecular Testing. *J Clin Microbiol* (2020), doi:10.1128/JCM.00995-20.
25. Shi, H. et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 20, 425-434 (2020), doi:10.1016/S1473-3099(20)30086-4.
26. Long, C. et al. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol* 126, 108961(2020), doi:10.1016/j.ejrad.2020.108961.
27. Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395, 507-513 (2020), doi:10.1016/S0140-6736(20)30211-7.
28. Reusken, C. et al. Laboratory readiness and response for novel coronavirus (2019nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. *Euro Surveill* 25 (2020), doi:10.2807/1560-7917.ES.2020.25.6.2000082.
29. Fomsgaard, A. S. & Rosenstjerne, M. W. An alternative workflow for molecular detection of SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. *Euro Surveill* 25 (2020), doi:10.2807/15607917.ES.2020.25.14.2000398.
30. Esbin, M. N. et al. Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection. *RNA* (2020), doi:10.1261/rna.076232.120.
31. Pabbaraju, K. et al. A Public Health Laboratory Response to the COVID-19 Pandemic. *Clin Microbiol* (2020), doi:10.1128/JCM.01110-20.
32. Vermeiren, C. et al. Comparison of Copan ESwab and FLOQSwab for COVID-19 Diagnosis: Working around a Supply Shortage. *J Clin Microbiol* 58 (2020), doi:10.1128/JCM.00669-20.
33. Kubik, M. J., Permenter, T. & Saremian, J. Specimen Age Stability for Human Papilloma Virus DNA Testing Using BD SurePath. *Lab Med* 46, 51-54 (2020); quiz e13, doi:10.1309/LM87NED5LRSELUOQ.
34. Kim, S. E. et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and p resymptomatic patients. *Int J Infect Dis* 95, 441-443 (2020), doi:10.1016/j.ijid.2020.04.083.
35. Sethuraman, N., Jeremiah, S. S. & Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. *JAMA* (2020), doi:10.1001/jama.2020.8259.
36. Schwierzeck, V. et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. *Clin Infect Dis* (2020),

doi:10.1093/cid/ciaa491.

37. Roxby, A. C. et al. Outbreak Investigation of COVID-19 Among Residents and Staff of an Independent and Assisted Living Community for Older Adults in Seattle, Washington. *JAMA Intern Med* (2020), doi:10.1001/jamainternmed.2020.2233.
38. Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* (2020), doi:10.1038/s41586-020-2196-x.
39. Druce, J., Garcia, K., Tran, T., Papadakis, G. & Birch, C. Evaluation of swabs, transport media, and specimen transport conditions for optimal detection of viruses by PCR. *J Clin Microbiol* 50, 1064-1065 (2020), doi:10.1128/JCM.06551-11.
40. Spackman, E., Pedersen, J. C., McKinley, E. T. & Gelb, J., Jr. Optimal specimen collection and transport methods for the detection of avian influenza virus and Newcastle disease virus. *BMC Vet Res* 9, 35 (2020), doi:10.1186/1746-6148-9-35.
41. Kontanis, E. J. & Reed, F. A. Evaluation of real-time PCR amplification efficiencies to detect PCR inhibitors. *J Forensic Sci* 51, 795-804 (2006), doi:10.1111/j.15564029.2006.00182.x (2006).
42. Almqvist, C. et al. Season of birth, childhood asthma and allergy in a nationwide cohort-Mediation through lower respiratory infections. *Clin Exp Allergy* 50, 222-230, doi:10.1111/cea.13542.
43. Callahan, C. J. et al. Open Development and Clinical Validation of Multiple 3DPrinted Sample-Collection Swabs: Rapid Resolution of a Critical COVID-19 Testing Bottleneck. *medRxiv* (2020), doi:10.1101/2020.04.14.20065094.
44. Roberts, T.C. et al. Detection and quantification of extracellular microRNAs in murine biofluids. *Biol Proced Online* 16:5.
45. To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 20, 565-574 (2020), doi:10.1016/S14733099(20)30196-1.
46. Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. *Ann Intern Med* (2020), doi:10.7326/M20-1495.
47. Winichakoon, P. et al. Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19. *J Clin Microbiol* 58 (2020), doi:10.1128/JCM.00297-20.
48. Young, B.E. et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA* (2020).
49. Lu, K. L., Chen, S. & Leung, L. P. Initial Experience of an Emergency Department in Shenzhen in Responding to the Emerging Wuhan Coronavirus Pneumonia. *Ann Emerg Med* 75, 556 (2020), doi:10.1016/j.annemergmed.2020.02.006.
50. Avaniss-Aghajani, E., Sarkissian, A., Fernando, F. & Avaniss-Aghajani, A. Validation of the Hologic's Aptima Unisex and Multitest Specimen collection kits used for Endocervical and Male Urethral Swab Specimen (Aptima Swab) for sample collection of SARS-CoV-2. *J Clin Microbiol* (2020), doi:10.1128/JCM.00753-20.

Figures

Figure 1

Figure 1

The positivity rate of SARS-CoV-2 RT-PCR as a function of the swab system used.

Figure 2

Figure 2

The sensitivity of SARS-CoV-2 RT-PCR depends on the swab system used.

Figure 3

Figure 3

Direct comparison of the in-house swab system with two previously validated collection sets.

Figure 4

Figure 4

Organic compounds affect the sensitivity of SARS-CoV-2 RT-PCR.

Figure 5

Figure 5

The stability of SARS-CoV-2 RNA in the in-house VTM.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementsNairzforsubmission.pdf](#)